Cystatin SN (CST1) Is a Poor Independent Prognostic Biomarker for Gastrointestinal Diffuse Large B-Cell Lymphoma

03 July 2024 : Clinical Research

Jie Wang^1ABCDEFG*, Ming Yang^2CD, Sheng Chen^2CEF, Hongbo Zhu^1AB, Zhirong Zhang^1CD

DOI: 10.12659/MSM.943551

Med Sci Monit 2024; 30:e943551

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 3 Prognostic significance of CST1 and clinicopathological factors.

Characters	Median OS time (month)	Univariate analysis			Multivariate analysis
Characters	Median OS time (month)	5-year OS rate%	HR	P*	HR	95% CI	P**
Gender
Male	68.2	73.4
Female	72.3	66.2	0.953	0.920
Age
≤60	73.2	71.9
>60	67.3	63.4	1.078	0.887
Tumor diameter (cm)
≤5	56.7	55.7
>5	75.5	75.4	0.572	0.237
Macroscopic type
Ulcerative	70.8	68.1
Polypoid	40.0	0.0
Others	75.3	79.1	0.807	0.521
Lesion number
Single	72.4	72.1
Multiple	72.0	64.2	0.952	0.931
Site
Stomach	68.3	68.0
Intestine	73.4	72.3	0.890	0.805
Chemotherapy
No	73.8	68.1
Yes	66.9	70.5	1.259	0.632
Serum LDH
Normal	82.0	82.7			1.00
High	45.6	44.1	4.178	0.002	2.80	0.98–8.00	0.054
PS
<2	76.5	75.9			1.00
2–4	46.7	30.3	4.015	0.003	4.21	1.47–12.06	0.007
Luanguo stage
I–II1	78.4	76.4			1.00
II2–IV	43.7	40.4	3.824	0.002	3.63	1.25–10.54	0.018
IPI
<3	74.8	72.6
3–5	31.3	23.8	5.243	0.001
CST1
Low	76.4	73.9			1.00
High	49.4	54.5	3.112	0.012	3.07	1.04–9.12	0.043
^* Log rank test; ^** Cox-regression model. LDH – lactate dehydrogenase; PS – performence status; IPI – International Prognostic Index; CST1 – Cystatin SN; HR – hazard ratio; CI – confident incidence.

Back to the Article